ENGINEERING THE NEXT GENERATION OF PRECISION BIOLOGICS
Expanding the Genetic Blueprint:
Novel Conjugation Sites Engineered with Synthetic Amino Acids that Improve Therapeutic Properties of Biologics
Delivering on the promise of antibody-conjugates and protein therapeutics
BrickBio's industry-leading expanded genetic code platform enables precise, multi-site conjugation of antibodies and proteins - Unlocking therapeutics with improved efficacy, safety, and therapeutic index.
Therapeutics have relied on suboptimal conjugation methods, resulting in a staggering number of failed therapeutics due to; heterogeneity, lack of stability, or lack of precise control of the conjugation site.
Optimal Conjugation Sites for Best-in-Class Molecules
BrickBio Identifies Stable Conjugation Sites to
Shield ADC Payloads and Optimize their Activity
-
BrickBio's mammalian expression systems enable efficient synthetic amino acid (conjugation handle) incorporation at any site within a protein backbone
-
Multiple tRNA/Amino Acid pairs allow for one step, multi-drug conjugation
-
-
SiteSelect Panel can predict and screen 50+ sites within weeks to optimize lead drug substance
-
Mammalian optimized tRNA's allow for antibodies, nanobodies, Oligonucleotides, and AAV to be modified with optimized conjugation handles
-
-
Existing conjugation technologies with unstable and limited sites lead to poor clinical outcomes
-
Previously inaccessible sites and various conjugation chemistries enable tunable biophysical characteristics and conjugation flexibility
BRKB-300: First-in-Class Optimized, High-Potency B7-H3 ADC
BRKB-300 contains a differentiated MOA payload to get around Topo resistance:
IND-Enabling studies in Progress
Safer, More Efficacious Therapeutics, with any Payload
BrickBio ADCs are 5x safer and more efficacious with Conjugation Alone than
other conjugation strategies with the same linker-payload
-
BrickADC therapeutic index outcompetes cysteine, other site-specific conjugation technologies, and FDA approved ADCs.
-
Improvements derived from: Novel Site of Conjugation, Stable Conjugation, Reduced Hydrophobicity, Tuned Exposure, Lower Hydrodynamic Radius, Optimized Cleavage Kinetics, Additional Biophysical Optimization
High-Throughput Site Prediction for Any Payload
Site-Selection Panel Algorithm is Driven by Thousands
of Empirical and Literature-Backed Data Points for Any Payload Structure
-
New or existing payload structures can be analyzed for optimal conjugation sites in silico (see above) and rapidly tested in vitro/in vivo, Saving Months of R&D
-
Reproducible prediction demonstrated with partnered and internal assets
PLATFORM
Expand the ADC Status Quo: Multi-Payload Conjugates
Combine multiple distinct payloads with synergistic mechanisms of action
for unprecedented patient outcomes
-
Multi-payload conjugation is performed in a one-pot reaction providing a simplified CMC process
-
First-in-Class stable CHO cell line for commercial scalability
-
Addresses unmet need: payload resistance, low efficacy, incomplete cancer immunity cycle
Beyond ADCs: Gene Therapy, Oligonucleotides, and Nanobodies
One platform. Any protein. Any payload. Targeted delivery across gene therapy, oligonucleotides, nanobodies, and beyond.
-
Control tissue delivery - without requiring extensive re-design
-
AAV: Precisely incorporate an unnatural amino acid at a defined capsid position, enabling precise controlled attachment of targeting ligands
-
Oligonucleotides: Modulate site of conjugation for improved stability, reduced hydrophobicity, and with various conjugation chemistries - any combination is possible
-
Nanobodies: Antibody fragments and VHH-based therapies become modular variables of an equation, overcoming first generation downfalls of genetic fusions with spatially defined chemical assembly
-
-
"A facile chemical strategy to synthesize precise AAV-protein conjugates for targeted gene delivery" demonstrates enhanced infectivity into HER2 positive tumors using BrickBio's chemical conjugation to attach full length antibodies to an AAV2 capsid.
Current Investors
Pipeline Snapshot
RECENT NEWS
Management Team
CEO, CO-FOUNDER,
TIGER GENE
SENIOR ADVISOR &
CHAIRMAN OF SAB
DIRECTOR OF CELL LINE ENGINEERING
SENIOR SCIENTIST, R&D
CHIEF BUSINESS OFFICER
Partners:
Bring us your Molecule. We'll Help You Make It Better
OUR ADDRESS
600 Winter Street
Waltham, MA, 02451, USA
For any general inquiries, please fill in the following contact form:
